Betz Stephen F. 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Jun 16, 2025
Insider Transaction Report
Form 4
Betz Stephen F.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2025-06-12$1.91/sh+71,525$136,613→ 180,551 total - Exercise/Conversion
Common Stock
2025-06-12$9.28/sh+16,645$154,466→ 197,196 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-12−16,645→ 58,198 totalExercise: $9.28Exp: 2028-05-24→ Common Stock (16,645 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-12−71,525→ 108,514 totalExercise: $1.91Exp: 2028-03-16→ Common Stock (71,525 underlying) - Sale
Common Stock
2025-06-12$32.23/sh−97,483$3,141,877→ 99,713 total
Footnotes (5)
- [F1]Includes 438 shares acquired under the Issuer's Employee Stock Purchase Plan.
- [F2]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F3]The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $32.23 per share. The range of sales prices on the transaction date was $31.67 to $32.65 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
- [F4]The option vested in 48 equal monthly installments beginning on April 16, 2018.
- [F5]The option vested in 48 equal monthly installments beginning on June 25, 2018.